DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Alliance
CEVEC and Généthon sign a collaboration agreement to develop
lentiviral vector packaging cell lines based on CEVEC's proprietary
CAP(R)GT technology
17.09.2015 / 08:00
---------------------------------------------------------------------
CEVEC and Généthon sign a collaboration agreement to develop lentiviral
vector packaging cell lines based on CEVEC's proprietary CAP(R)GT
technology
- Agreement enables fully scalable, industrial lentivirus vector
production
- Collaboration represents an important step in the roll-out of CEVEC's
strategy to position CAP(R)GT technology as the industrial standard for
the production of lentiviral vectors for commercial gene therapy
applications
Cologne, Germany, September 17, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC),
the expert in the production of tailor-made recombinant glycoproteins and
gene therapy vectors, today announced a collaboration agreement with
Généthon (Evry, France) for the development and exploitation of lentivirus
packaging cell lines based on CEVEC's proprietary CAP(R)GT technology.
Under the terms of the agreement, CEVEC will grant Généthon a license for
the development of lentivirus packaging cell lines based on CEVEC's
CAP(R)GT technology to be used with its own portfolio of gene therapy
products in the field of rare diseases. Furthermore, Généthon will offer
its development and production expertise to manufacture CAP(R)GT derived
lentiviral vectors for its partners. CEVEC will offer the required licenses
for its CAP(R)GT technology to Généthon's partners. Financial details of
this agreement were not disclosed.
"Généthon is an important player with huge experience in developing gene
therapies for rare diseases with several products in clinical development.
The agreement with Généthon is a strong endorsement of our CAP(R)GT system
and represents a major step in the roll-out of our strategy to position our
platform as the technology of choice for commercial production of
lentiviral vectors for gene therapy applications," commented Frank Ubags,
Chief Executive Officer of CEVEC Pharmaceuticals GmbH. "We are seeing an
increasing interest in our unique system as more and more gene therapy
programs need scalable manufacturing capabilities."
With its CAP(R)GT cell lines, CEVEC provides a novel platform for the
industrial production of viral vectors for gene therapy applications.
Growing in serum-free suspension cultures, CAP(R)GT provides outstanding
production capabilities and high cell densities allowing for easier
scale-up and reduced production costs when compared to adherent cell
culture systems including HEK293.
About Généthon:
Généthon, created by the AFM-Telethon, has the mission to make innovative
gene therapy treatments available to patients affected with rare genetic
diseases.
Having played a pioneering role in deciphering the human genome, Généthon
is today, with more than 200 scientists, physicians, engineers and
regulatory affairs specialists, one of the leading organizations for the
development of gene therapy treatments. Généthon has also built one of the
largest sites worldwide for GMP production of gene therapy products,
Généthon Bioprod. In 2012, Généthon was awarded the prestigious Prix Galien
for Pharmaceutical Research (France). In 2015, Généthon was one of 16
winners of the World Innovation Competition 2030 for its project on the
development of an industrial process for production of gene therapy
vectors.
The pipeline of Généthon includes products currently in international
clinical trials and at preclinical stages, for immune deficiencies,
muscular dystrophies, ocular and liver diseases. These products are
developed either with Généthon as sponsor, or in partnership with private
companies and academic institutions.
About CEVEC:
Privately held CEVEC, based in Cologne, Germany, is an expert for the
production of tailor-made recombinant glyco-proteins and gene therapy
vectors. The Company's core technologies, CAP(R)Go and CAP(R)GT are based
on a unique human cellular expression system.
The CAP(R)Go expression platform comprises a portfolio of glyco-optimized
human suspension cell lines for tailor-made glycosylation of recombinant
proteins. The cells are highly efficient for the production of a broad
range of difficult to express glycoproteins and provide authentic human
post-translational modifications. CAP(R)Go has proven to enhance the
activity, stability and serum half-life of several candidate proteins.
The CAP(R)GT expression platform provides a fully scalable, regulatory
endorsed production system for gene therapy vectors. CAP(R)GT cells grow to
high cell densities and show a broad viral propagation spectrum including
lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).
Furthermore, CAP(R)GT enables easier scale-up and reduced production costs
when compared to adherent cell culture systems.
Research collaborations with international pharmaceutical and biotechnology
partners followed by licensing agreements for the technology form one
revenue base for CEVEC. In addition, the Company provides contract
manufacturing for the cGMP production in CAP(R)Go and CAP(R)GT cells.
Contact:
<pre>
CEVEC Pharmaceuticals GmbH MC Services AG
Frank Ubags Anne Hennecke
Chief Executive Officer Public Relations
T.:+49 221 46020800 T.: +49 211 52925222
E.: ubags@cevec.com E.: anne.hennecke@mc-services.eu
</pre>
www.cevec.com
---------------------------------------------------------------------
17.09.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
395129 17.09.2015
DGAP-News: CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC's proprietary CAP(R)GT technology
| Source: EQS Group AG